Sands Capital Alternatives, LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Acumen Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (ABOS)

Filing Manager: Sands Capital Alternatives, LLC
Reporting Manager: Sands Capital Alternatives, LLC
Security: Acumen Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share
Symbol: ABOS
Shares outstanding: 61,019,196 shares
Disclosed Ownership: 3,417,075 shares
Ownership: 5.6%
Form type: SCHEDULE 13G/A
Filing time: 13 Aug 2025, 11:27:31 UTC
Date of event: 30 Jun 2025
SEC: View on sec.gov

Reporting Managers (5)

Name	Ownership	Shares Owned	shared voting power	Signature	Title
Sands Capital Alternatives, LLC	5.6%	3,417,075	3,417,075	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel
Sands Capital Ventures Discovery Fund III, L.P.	1.9%	1,124,729	1,124,729	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel of the General Partner of Sands Capital Ventures Discovery Fund III, L.P.
Sands Capital Global Venture Fund II, L.P.	1.9%	1,146,173	1,146,173	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Global Venture Fund II, L.P.
Sands Capital Life Sciences Pulse Fund, LLC	1.9%	1,146,173	1,146,173	/s/ Jonathan Goodman	Jonathan Goodman, General Counsel
SANDS FRANK M.	5.6%	3,417,075	3,417,075	/s/ Frank M. Sands	Frank M. Sands